Neurodegenerative diseases like Alzheimer’s and Parkinson’s are partly attributable to brain inflammation. Researchers at the Swedish medical university Karolinska Institutet in Sweden now demonstrate in a paper published in Nature that a well-known family of enzymes can prevent the inflammation and thus constitute a potential target for drugs.
Research suggests that microglial cells — the nerve system’s primary immune cells — play a critical part in neurodegenerative diseases, such as Alzheimer’s and Parkinson’s. The over-activation of these cells in the brain can cause inflammation, resulting in neuronal death.
Scientists at Karolinska Institutet and Seville University, working in collaboration with colleagues at Lund University, have now found a way to prevent the activation of the microglia and consequently the inflammation they cause. The key is the blocking of enzymes called caspases, which the team has shown control microglial activation.
“The caspases are a group of enzymes known for causing cell death,” says Associate Professor Bertrand Joseph, who headed the study. “That they also serve as signal molecules that govern that activity of other cells was an unexpected discovery that gives them an entirely new physiological role.”
By studying cell cultures and mice, the researchers show that certain caspases (3, 7 and 8) activate rather than kill microglial cells, which triggers an inflammatory reaction. Mice given caspase inhibitors displayed fewer activated microglia and less inflammation and cell death in the surrounding neurons.
They also examined samples from deceased Alzheimer’s and Parkinson’s patients and discovered a higher incidence of activated caspases in their microglial cells.
“We’ll now be examining whether the substances that inhibit the caspases can be candidates for useful drugs in the treatment of certain neurological diseases,” says Dr Joseph.
Publication: ‘Caspase signaling controls microglia activation and neurotoxicity’, Miguel A. Burguillos, Tomas Deierborg, Edel Kavanagh, Annette Persson, Nabil Hajji, Albert Garcia-Quintanilla, Josefina Cano, Patrik Brundin, Elisabet Englund, Jose L. Venero & Bertrand Joseph, Nature, AOP 9 March 2011, doi:10.1038/nature09788.
For further information, please contact:
Bertrand Joseph, Associate Professor
Department of Oncology-Pathology
Tel: +46 (0)8 517 73 826
Mobile: +46 (0)73 706 7110
Download photo and contact the Press Office: ki.se/pressroom
Karolinska Institutet is one of the world’s leading medical universities. It accounts for over 40 per cent of the medical academic research conducted in Sweden and offers the country’s broadest range of education in medicine and health sciences. Since 1901 the Nobel Assembly at Karolinska Institutet has selected the Nobel laureates in Physiology or Medicine.